BACKGROUND/AIMS: Interleukin-10 (IL-10) has been ascribed pro-viral but anti-fibrotic properties in chronic hepatitis C virus (HCV) infection. In this study, we examined the role of HCV-specific T-cell IL-10 response in patients with acute and chronic HCV infection. METHODS: Peripheral HCV-specific T-cell IL-10 and IFNgamma responses were measured in cytokine Elispot assay using overlapping HCV-derived peptides in patients with chronic (n=61), resolved (n=15) and acute (n=8) hepatitis C, looking for their onset, quantity, breadth and durability relative to clinical and virological outcomes. The source and effect of HCV-specific IL-10 response were determined in depletion and IL-10 neutralization experiments. RESULTS: Both HCV-specific IL-10 and IFNgamma responses were detected early within 1-2 months of acute clinical hepatitis C. However, only HCV-specific IL-10 response correlated with elevated liver enzymes, increased viremia and suppressed HCV-specific CD4(+) T-cell proliferation in acute infection. While these associations were lost in established chronic infection, HCV-specific IL-10 responses were increased in patients without cirrhosis while IL-10 blockade enhanced antiviral effector IFNgamma responses. CONCLUSIONS: HCV-specific IL-10 Tr1 responses may play a dual role in HCV infection, dampening effector T-cells to promote viral persistence in acute infection but also protecting against progressive fibrosis in chronic infection.
BACKGROUND/AIMS: Interleukin-10 (IL-10) has been ascribed pro-viral but anti-fibrotic properties in chronic hepatitis C virus (HCV) infection. In this study, we examined the role of HCV-specific T-cell IL-10 response in patients with acute and chronic HCV infection. METHODS: Peripheral HCV-specific T-cell IL-10 and IFNgamma responses were measured in cytokine Elispot assay using overlapping HCV-derived peptides in patients with chronic (n=61), resolved (n=15) and acute (n=8) hepatitis C, looking for their onset, quantity, breadth and durability relative to clinical and virological outcomes. The source and effect of HCV-specific IL-10 response were determined in depletion and IL-10 neutralization experiments. RESULTS: Both HCV-specific IL-10 and IFNgamma responses were detected early within 1-2 months of acute clinical hepatitis C. However, only HCV-specific IL-10 response correlated with elevated liver enzymes, increased viremia and suppressed HCV-specific CD4(+) T-cell proliferation in acute infection. While these associations were lost in established chronic infection, HCV-specific IL-10 responses were increased in patients without cirrhosis while IL-10 blockade enhanced antiviral effector IFNgamma responses. CONCLUSIONS:HCV-specific IL-10 Tr1 responses may play a dual role in HCV infection, dampening effector T-cells to promote viral persistence in acute infection but also protecting against progressive fibrosis in chronic infection.
Authors: F Bolacchi; A Sinistro; C Ciaprini; F Demin; M Capozzi; F C Carducci; C M J Drapeau; G Rocchi; A Bergamini Journal: Clin Exp Immunol Date: 2006-05 Impact factor: 4.330
Authors: Nadia Alatrakchi; Camilla S Graham; Hans J J van der Vliet; Kenneth E Sherman; Mark A Exley; Margaret James Koziel Journal: J Virol Date: 2007-03-21 Impact factor: 5.103
Authors: K M Chang; R Thimme; J J Melpolder; D Oldach; J Pemberton; J Moorhead-Loudis; J G McHutchison; H J Alter; F V Chisari Journal: Hepatology Date: 2001-01 Impact factor: 17.425
Authors: J K Flynn; G J Dore; M Hellard; B Yeung; W D Rawlinson; P A White; J M Kaldor; A R Lloyd; R A Ffrench Journal: J Viral Hepat Date: 2010-07-05 Impact factor: 3.728
Authors: Keisuke Ojiro; Xiaowang Qu; Hyosun Cho; Jang-June Park; Annelise Vuidepot; Nikolai Lissin; Peter E Molloy; Alan Bennett; Bent K Jakobsen; David E Kaplan; James L Riley; Kyong-Mi Chang Journal: J Virol Date: 2017-04-28 Impact factor: 5.103
Authors: Andrea L Cox; Kimberly Page; Julie Bruneau; Naglaa H Shoukry; Georg M Lauer; Arthur Y Kim; Hugo R Rosen; Hank Radziewicz; Arash Grakoui; Daniel S Fierer; Andrea D Branch; David E Kaplan; Kyong-Mi Chang Journal: Gastroenterology Date: 2008-12-04 Impact factor: 22.682